<DOC>
	<DOC>NCT01122875</DOC>
	<brief_summary>This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>ECOG performance status of 0, 1, or 2 Life expectancy of at least 12 weeks Histologic documentation of previously treated t(4;14)positive multiple myeloma for which no effective standard therapy exists Prior use of any monoclonal antibody before study treatment Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any other investigational anticancer agent within 4 weeks of study treatment Completion of autologous stem cell transplant within 6 months prior to study treatment Prior allogeneic stem cell transplant History of severe allergic or anaphylactic reactions to monoclonal antibody therapy Evidence of significant, uncontrolled concomitant diseases, including significant cardiovascular disease or pulmonary disease Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening or any recent major episode of infection requiring treatment with IV antibiotics or hospitalization prior to study treatment Recent major surgery (prior to study treatment), other than for diagnosis Presence of positive test results for Hepatitis B or Hepatitis C Known history of HIV seropositive status Women who are pregnant or lactating Childbearing potential without agreement to use effective form of contraception for the duration of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>